X4 Pharmaceuticals Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 72
Employees
  • Stock Symbol
  • XFOR
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $8.10
  • (As of Tuesday Closing)

X4 Pharmaceuticals General Information

Description

X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 61 North Beacon Street
  • 4th Floor
  • Boston, MA 02134
  • United States
+1 (857) 000-0000

X4 Pharmaceuticals Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

X4 Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.10 $8.39 $5.38 - $11.11 $192M 23.7M 144K -$3.84

X4 Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 109,420 46,881 119,061 3,194
Revenue 0 3,000 0 0
EBITDA (66,257) (59,217) (51,754) (32,698)
Net Income (69,669) (62,131) (52,807) (33,285)
Total Assets 161,035 122,871 160,698 36,004
Total Debt 39,810 38,448 22,913 7,894
Public Fundamental Data provided by Morningstar, Inc. disclaimer

X4 Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore X4 Pharmaceuticals‘s full profile, request access.

Request a free trial

X4 Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore X4 Pharmaceuticals‘s full profile, request access.

Request a free trial

X4 Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system functio
Biotechnology
Boston, MA
72 As of 2020
00000
000000000 00000

0000 000

m ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat
0000000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000

0000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Boston, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

X4 Pharmaceuticals Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
0000000 000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
000000000 Formerly VC-backed Rockville, MD 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Watertown, MA 00 00000 000000000 00000
You’re viewing 5 of 37 competitors. Get the full list »

X4 Pharmaceuticals Executive Team (19)

Name Title Board Seat Contact Info
Paula Ragan Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Adam Mostafa Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Arthur Taveras Ph.D Chief Scientific Officer
Andrea Franz Financial Consultant
Keith Flaherty MD Co-Founder
You’re viewing 5 of 19 executive team members. Get the full list »

X4 Pharmaceuticals Board Members (11)

Name Representing Role Since
Alison Lawton X4 Pharmaceuticals Board Member 000 0000
David McGirr Arsanis Board Member 000 0000
Gary Bridger Ph.D X4 Pharmaceuticals Board Member 000 0000
Isaac Blech Self Board Member 000 0000
Isaac Blech Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

X4 Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

X4 Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 13-Mar-2019 000000000000000000 000.00 Biotechnology 00000 00000 00.0
To view X4 Pharmaceuticals’s complete acquisitions history, request access »